Malin Corporation, a newly-incorporated Irish-based global life sciences company, says it has raised up to 330 million euros ($347 million) made up of committed gross proceeds and additional investment commitments. Malin also said it will list on the ESM of the Irish Stock Exchange on March 25, 2015.
Malin has already identified and entered into acquisition and investment agreements or binding heads of agreement with seven operating companies (listed below), which meet its criteria, and has total committed expenditure in respect of these companies of around 100 million euros with a further amount of up to about 130 million euros of follow-on investment options or investments subject to contingent commitments. Malin will also seek to make a number of further acquisitions and investments post its flotation.
Assets to be acquired
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze